openPR Logo
Press release

Genetic Disorders Market to Grow at a CAGR of 13.68%, Leading Players Amicus Therapeutics, Inc.; Alexion Pharmaceuticals, Inc.; Sanofi; Takeda Pharmaceutical Company Limited; Vertex Pharmaceuticals Incorporated

10-21-2020 08:40 PM CET | Health & Medicine

Press release from: Data Bridge Market Research

Genetic Disorders Market

Genetic Disorders Market

Genetic Disorders Market is expected to register a healthy CAGR of 13.68% in the forecast period of 2019-2026. The report contains data from the base year of 2018 and the historic year of 2017. This rise in market value can be attributed to the focus of various pharmaceutical organizations on development of specialized therapies for treatment of genetic disorders. Some are the key players taken under coverage for this study are Amicus Therapeutics, Inc.; Alexion Pharmaceuticals, Inc.; Sanofi; Takeda Pharmaceutical Company Limited; Vertex Pharmaceuticals Incorporated; F. Hoffmann-La Roche Ltd; Abbott; Amgen Inc.; ELITechGroup; GW Pharmaceuticals plc; Thermo Fisher Scientific Inc.; Pfizer Inc.; PerkinElmer Inc.; AutoGenomics; Bio-Rad Laboratories, Inc.; BioMarin; Sarepta Therapeutics among others.

Click to Get Global Genetic Disorders Market Research Sample PDF Copy Here @ 

Data Bridge Market Research released a new market study on Global Genetic Disorders Market with market data Tables, Pie Chart, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The research report presents a complete assessment of the market and contains a future trend, current growth factors, attentive opinions, facts, and industry-validated market data.

Market Definition: Global Genetic Disorders Market

Genetic disorders inherited disorders that are passed onto the next-generation by gene transferring from one generation to the others. These disorders are highly complicated and rare to treat and require specialized treatments/therapeutics for their improvements and reduced prevalence amongst patients. These disorders are generally characterized as life-threating and are progressive in nature with each disease carrying different symptoms. Currently, the pipeline for treatment of these disorders is abundant with a number of therapeutics currently in the late-stage of their trials.

Market Drivers

Prevailing cases of genetic and chronic disease along with the increasing government initiatives in creating awareness regarding the genetic test and diagnosis; acts as a driver for the growth of this market
Significant volume and strength of pipeline drugs and therapies for genetic disorders; this factor is expected to boost the growth of the market
Increasing technological advancement and R&D funding is another factor which will surge the market growth
Increasing prevalence of drugs being approved in the recent years along with various drugs entering their last or late-stage of development; this factor is expected to propel the growth of the market

Market Restraints

Significant prevalence and attrition towards reduction of drugs in clinical trial for genetic disorders; this factor is expected to hinder the growth of the market
High costs associated with the diagnosis and identification of genetic disorders can restrict the market growth
Complications related to social and ethical categories with the utilization of genetic testing; this factor is expected to act as a restraint in the market growth

Segmentation: Global Genetic Disorders Market

By Indication

Cystic Fibrosis (CF)
Duchenne Muscular Dystrophy (DMD)
Lysosomal Storage Disease (LSD)
Paraoxysmal Nocturnal Hemoglobinuria (PNH)

By Disease Type

Alzheimer’s Disease
Cystic Fibrosis
Sickle Cell Anemia
Duchenne Muscular Dystrophy (DMD)
Huntington’s Disease
Rare Diseases

By Geography

North America
Rest of Europe
South Korea
Rest of Asia-Pacific
South America
Rest of South America
Middle East and Africa
South Africa
Rest of Middle East and Africa

Order a Copy of This Research Report @

Key Developments in the Market:

In June 2019, Vertex Pharmaceuticals Incorporated announced that they had expanded their gene editing capabilities for the development of novel therapies in Duchenne Muscular Dystrophy (DMD) and Myotonic Dystotrophy Type 1 (DM1) with the help of an expansion on the existing collaboration with CRISPR Therapeutics along with the acquisition of Exonics Therapeutics
In August 2018, U.S. FDA announced that they had approved “Galafold (migalastat)”, first approved oral medication for the treatment of “Fabry” disease having a genetic mutation responsive towards treatment with “Galafold”. The U.S. FDA has granted the approval for the drug to Amicus Therapeutics, Inc. having received accelerated approval pathway with the most extreme reactions against the drug being headache, throat & nasal irritation, fever, nausea and urinary tract infection

Competitive Analysis:

Global genetic disorders market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of genetic disorders market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Reasons to Purchase this Report

Current and future of global genetic disorders market outlook in the developed and emerging markets
The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
Regions/Countries that are expected to witness the fastest growth rates during the forecast period
The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

All segmentation provided above in this report is represented at country level
All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Get Full TOC @


Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475


About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to complex business challenges and initiates an effortless decision-making process.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Genetic Disorders Market to Grow at a CAGR of 13.68%, Leading Players Amicus Therapeutics, Inc.; Alexion Pharmaceuticals, Inc.; Sanofi; Takeda Pharmaceutical Company Limited; Vertex Pharmaceuticals Incorporated here

News-ID: 2167507 • Views: 894

More Releases from Data Bridge Market Research

Global Fitness App Market to Witness Huge Growth by Worldwide| Global Current Tr …
Data Bridge Market Research has recently added a concise research on the Global Fitness App Market to depict valuable insights related to significant market trends driving the industry. Global Fitness App Market report suggests that industry is anticipated to witness higher growth during the forecast period due to growing demand at the end user level. This report is the best overview about global industry perspective, comprehensive analysis, size, share, growth,
Digital Agriculture Market To 2020 -2027 Trends-Industry Share, Size, Top Manufa …
To prepare market research report, certain steps are to be followed for collecting, recording and analysing market data. Digital Agriculture Market research report identifies and analyses the emerging trends along with major drivers, inhibitors, challenges and opportunities in the market. In this era of globalization, the whole world is the marketplace and hence businesses seek to adopt a global market research report. This is a professional and in depth market
Modular Construction Market To 2020 -2027 Development Insight and Manufacturers …
To thrive in this rapidly transforming marketplace, today’s businesses call for innovative and superlative solutions. The Modular Construction Market report covers the existing market size of the Modular Construction industry alongside the growth rate throughout the years. The top to bottom data by a different segment of market showcase empowers administrators to screen future gainfulness and settle on fundamental choices for practical development. The report focuses on major driving factors
Wood Pellet Market To 2020 -2027 Industry Insights, Trends and Forecast | Drax G …
An influential Wood Pellet Market report carries out an evaluation of the growth rate and the market value of Wood Pellet industry based on market dynamics and growth inducing factors. Thorough market analysis covered in this report by skilled experts gives every bit of knowledge which is imperative to design and align with current market scenarios. This market research report is one-stop archive for in-depth knowledge of market analytics aggregated

All 5 Releases

More Releases for Genetic

Preimplantation Genetic Testing Market is Blooming Worldwide
HTF MI recently introduced Global Preimplantation Genetic Testing Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2023. At present, the market is developing its presence and some of the key players from the complete study are F. Hoffmann-La Roche, Abbott Laboratories, Thermo Fisher Scientific, Natera, Illumina & Perkin Elmer etc. The market Study is segmented by key regions which
Genetic Analysis ASProduct Pipeline Analysis, 2017 Update
"The Report Genetic Analysis ASProduct Pipeline Analysis, 2017 Update provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. -" About Genetic Analysis ASProduct Market Genetic Analysis AS (Genetic Analysis) is a molecular diagnostic company that mapping of microbiota by utilizing the GA-map technology to develop IVD tests in various diseases. The company develops gene-based routine tests for the mapping and diagnosis of
Preimplantation Genetic Diagnosis: Scope & Revenue Outlook
Rising numbers of assisted reproductive procedures such as in vitro fertilization (IVF) is Asia is the most prominent factor driving the market for preimplantation genetic diagnosis. This is, in essence, the result of factors such as the delayed age of conception among Asian women, the rising rate of infertility among the population, and the significantly expanding medical tourism industry in the region. Rising disposable incomes and increased awareness regarding the
India Genetic Testing Market Analysis
India is witnessing an accelerating shift towards the prevalence of non-communicable diseases, having secured third position in congenital malformations and genetic disorders as the commonest causes of mortality in neonates in cities. The ability to identify these non-communicable diseases at an early stage lies within the genetic screening segment. Genetic screening, however, is still in its infancy and there are many challenges that need to be overcome in order to
Genetic Testing Services Market Analysis – 2023
Genetic testing is one of the most rapidly growing segments in molecular diagnostics industry that helps in delivering customized health services and is also called as personalized medicine. The genetic testing services include genetic testing, results interpretation, information analysis, education and counseling. Growing know-how about genetic testing, technological advances in genetic sequencing, rising incidences of genetic diseases especially cancer is the major factors propelling the genetic testing services market. Currently
Preimplantation Genetic Diagnosis - Saving Offsprings From Any Genetic Disorder
The market for preimplantation genetic diagnosis (PGD) in Asia features high fragmentation when it comes to diagnostic service providers. The large number of local players has intensified the competitive rivalry in the region. However, owing to the lack of better alternatives to PGD, costs of these procedures remain high, a major limiting factor for the market, especially in cost-sensitive developing countries in the region. A recent report by TMR suggests that